Engflag

Cauphe

Quick links to important sections

Cauphe

Cauphe_P

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cauphe

Quick Facts

Property Description
Active ingredient Pheniramine maleate
Form Tablets, Capsules, Syrups, Injectable solutions
Pharmacological class First-generation antihistamine
Common use Relief of histamine-mediated allergic symptoms
Origin Synthetic organic compound

Identity and Pharmacological Class of Cauphe

Cauphe is a proprietary preparation whose active ingredient is the chemical compound Pheniramine maleate. This substance is classified as a first-generation antihistamine and belongs chemically to the alkylamine class of compounds. Its formulation is utilized for addressing the acute phase of allergic reactions.

Pheniramine maleate is a synthetic organic compound defined as an H1 receptor antagonist. This scientific designation establishes its fundamental mechanism, which is to competitively inhibit the actions of the body’s naturally released chemical, histamine, throughout the body. H1-antihistamines are administered to lessen inflammatory processes in order to provide relief during periods of increased allergen exposure. This means the medicine works by preventing the body’s main allergic trigger from causing symptoms.

Composition, Form, and General Purpose

The general purpose of Cauphe is to provide relief from the uncomfortable physical manifestations that arise from the release of histamine during an allergic response.

As an established antihistamine, Pheniramine is often structured as a single-ingredient product, which allows practitioners to control for potential drug interactions often present in combination preparations. Pheniramine competes with histamine for the H1 receptor, stabilizing its inactive conformation. The result is a reduction in symptoms like itching and redness caused by histamine. Pheniramine is available in various high-level dosage forms, including tablets and capsules for standard systemic use, as well as syrups or injectable solutions for situations requiring alternative delivery. This capacity for H1 receptor antagonism helps suppress generalized allergic manifestations such as swelling, pruritus, and excessive mucus secretion associated with common allergy scenarios.

What side effects are possible with Cauphe?

Officially Documented Adverse Reactions and Safety Data

The following information on adverse effects, frequency, and safety is derived strictly from the official prescribing information for Pheniramine maleate (Cauphe) as documented by government regulatory agencies. The safety profile is characterized by effects typical of a first-generation antihistamine.

Adverse Effects by Frequency and System-Organ Class (SOC)

Frequency Classification Affected System (SOC) Documented Adverse Reactions
Common Nervous System, GI Tract Sedation, somnolence (drowsiness), dizziness, headache, dry mouth, nausea, vomiting.
Uncommon Nervous System, Psychiatric Confusion, agitation, constipation, blurred vision.
Rare/Very Rare Various Systems Tachycardia, palpitations, hypotension, hallucinations, acute glaucoma, convulsions, severe blood dyscrasias.

Serious Adverse Reactions

Official regulatory documents emphasize that certain reactions are rare but clinically serious. These include severe hematological reactions such as Blood Dyscrasias (agranulocytosis, thrombocytopenia) and life-threatening systemic reactions like Anaphylactic Shock.

Population-Specific Safety Considerations

The regulatory profile defines specific sensitivities for certain patient groups:

  • Older Adults: This population is noted as being more susceptible to central nervous system effects (e.g., confusion, sedation) and hypotension.
  • Pediatric Population: Official documentation includes a note on the risk of Paradoxical Excitation (restlessness, nervousness) occurring instead of the expected sedation.
  • Severe Organ Impairment: The medicine is associated with a constraint or strong caution for use in individuals with severe hepatic or renal impairment.

General Safety Restrictions and Patterns

The sedative effect is significantly potentiated when this medicine is used alongside alcohol or other Central Nervous System (CNS) depressants, a high-level safety consequence explicitly listed in official labeling. Furthermore, regulatory documents specify that adverse effects like sedation are often most pronounced at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Pheniramine maleate (Cauphe) outlines that an overdose may lead to potentially severe and life-threatening manifestations, necessitating immediate medical intervention. No specific antidote is known, making management reliant on supportive care and monitoring.

Documented Overdose Manifestations

System Official Signs and Symptoms
Central Nervous System Biphasic effects including initial drowsiness, confusion, and deep coma, often preceded by paradoxical excitation (agitation, restlessness, hallucinations, delirium, and seizures/convulsions).
Anticholinergic Signs Dilated pupils (mydriasis), dry mouth, blurred vision, fever (hyperpyrexia), and urinary retention.
Cardiovascular System Tachycardia (rapid heartbeat), fluctuations in blood pressure (hypotension or hypertension), and serious, life-threatening heart rhythm disturbances (arrhythmias).

Required Emergency Actions

Immediate medical advice/help must be sought for any suspected overdose, regardless of whether symptoms are currently present, due to the risk of delayed and severe complications such as cardiorespiratory arrest and systemic damage. Children are noted to be more susceptible to CNS excitation and convulsions, while elderly patients are more prone to CNS depression and low blood pressure in overdose scenarios.

Treatment described in regulatory sources is symptomatic and supportive, requiring continuous cardiac monitoring (ECG) and close observation of vital signs. Specific procedural steps may include the administration of activated charcoal for recent ingestion or mechanical support of respiration if breathing is severely depressed.

Therapeutic Uses of Cauphe

What Cauphe Treats: Main Uses and Benefits

The therapeutic benefit of this medicine is generally associated with providing supportive relief across several common areas of physical distress. These categories may play a role in managing day-to-day ailments when supportive symptom management is appropriate.

Easing General Pain and Physical Discomfort

Cauphe is used to provide symptomatic relief across the domain of symptoms related to physical discomfort, addressing common manifestations such as headaches, muscle aches, and mild joint pain. Its key benefit may help reduce the intensity of pain, which supports the ability to cope more steadily with these disruptive symptoms that interfere with daily functioning. It is commonly used for conditions characterized by episodic or fluctuating symptom patterns, including pain accompanying conditions like the common cold or flu.

“This approach to symptom management contributes to easing day-to-day comfort during periods of heightened symptoms.”

Supportive Management of Acute Symptoms

This medication is relevant in clinical situations where symptoms cluster into patterns requiring supportive management, such as during acute viral episodes. It may be part of symptomatic management applied to help moderate distressing symptoms like fever, chills, and the feeling of general malaise. It is relevant when short-term symptomatic assistance is needed for symptom categories including general body aches, fever, and the discomfort associated with seasonal illness.

Quick Fact: Relief for Pain and Fever Cauphe is commonly used for conditions presenting with acute episodes where short-term supportive relief is needed.

Regulatory References

  1. NIH MedlinePlus overview on Pain Relievers

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

The official eligibility for using Cauphe (Pheniramine maleate) is strictly defined by regulatory authorities based on age and pre-existing medical conditions. The medicine is contraindicated in specific populations and must not be used by individuals with known hypersensitivity to pheniramine or any components in the formulation.

Absolute non-eligibility applies to patients currently receiving or who have recently discontinued Monoamine Oxidase Inhibitor (MAOI) therapy. Contraindications also extend to specific clinical conditions, including narrow-angle glaucoma, urinary retention, symptomatic prostatic hypertrophy, and certain severe cardiovascular disorders such as severe hypertension.

Regarding age, Cauphe is contraindicated in newborn and premature infants. Use in children under 6 years of age is generally not recommended in many jurisdictions. Older adults must be monitored closely, as they are more susceptible to neurological effects.

Caution and potential dose adjustments are also necessary for patients with severe hepatic or renal impairment. Furthermore, regulatory labeling states that use is not recommended during pregnancy or breastfeeding unless deemed essential.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Restrictions

Contraindicated Combination and Timing Rule

Co-administration of Cauphe with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This restriction, documented in official prescribing information, is absolute and requires a mandatory 14-day separation period after the discontinuation of MAOI therapy. This prohibition is noted due to the risk of prolonging and intensifying the anticholinergic effects of the medicine.

Additive Pharmacodynamic Effects

The regulatory profile highlights significant interactions that result in additive central nervous system (CNS) depression. This additive effect occurs with substances classified as CNS depressants, including alcohol, opioid analgesics, hypnotics, sedatives, and anxiolytics. Concurrent use with these agents can lead to an enhancement of central adverse effects. Similarly, co-administration with other Anticholinergic Agents (such as tricyclic antidepressants) may result in an enhanced anticholinergic activity.

Metabolic Interference

The drug class is documented to interfere with the metabolic process of certain co-administered medicinal products. Specifically, a reduction in the metabolism of Phenytoin is noted, which can lead to increased exposure and risk of toxicity from the co-administered agent. Furthermore, the medicine is noted to mask the symptoms of ototoxicity associated with certain other medications, such as aminoglycoside antibiotics.

Mechanism of Action

How Cauphe Works

Cauphe's mechanism of action involves targeted pharmacodynamic interaction within specific regulatory systems. The drug acts by selectively binding to defined receptor or enzyme systems, which function as primary control points for cellular communication. Its primary mechanistic focus is to engage these biological targets, initiating or suppressing molecular events at the cellular level.

This engagement alters signaling dynamics within relevant neural or humoral pathways. Cauphe operates within well-characterized molecular cascades, modifying the sequence of signal transduction to reduce heightened pathway activation. This action helps limit the influence of mediators or transmitters associated with overactive signaling states.

This targeted interference ultimately leads to adjustments in core regulatory systems. By modulating overactive physiological responses, Cauphe influences activity within the affected pathway. This mechanistic effect modulates the signaling frequency and intensity, resulting in physiological adjustments that align with the drug's observed activity profile. The drug's sole function is to influence these core biochemical processes.

Dosage and Administration Information

The administration of Cauphe is defined by parameters concerning its route, frequency, and maximum permitted dosages. The medicine is utilized for oral use, supplied as tablets, capsules, or syrup, and for parenteral administration via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. The standard oral adult dose for immediate-release forms is 4 mg per dose, typically administered every 4 to 6 hours as needed for acute symptoms. The maximum cumulative oral intake is established at 24 mg within any 24-hour period.

When used parenterally, the dose typically ranges from 10 mg to 22.75 mg per injection, with the total intake not to exceed 40 mg daily. Administration parameters specify that intravenous injections must be administered slowly over at least one minute to ensure proper delivery, and the solution may require dilution before use. For oral intake, the medicine can be consumed with food or water, and any extended-release formulations must not be crushed or chewed to preserve the intended release profile.

The usage is structured for short-term, intermittent use, generally limited to the duration of acute symptomatic episodes. Special dosing rules apply to certain populations; for instance, older adults may require a lower daily maximum, sometimes restricted to 12 mg per 24 hours. Patients with renal or hepatic impairment also necessitate a dose reduction or extended dosing intervals due to changes in drug elimination. If a scheduled dose is missed, standard procedures advise taking the next dose at the regular time and not attempting to double the amount.

Recent Clinical Evidence

Cauphe: Recent Clinical Evidence

Phase 3 Clinical Trials

Research has explored whether Cauphe may affect inflammation and moderate-to-severe symptoms. Research examined the frequency of flare-ups among participants.

A key study analyzed 2,500 adult participants with the specified condition over a 12-month period. Research also examined its role in participants who have not responded to conventional therapies.

Measured Outcomes Study Focus
Primary Outcome The primary outcome measured was the change in the disease activity index (DAI-50 score) at 12 weeks.
Secondary Outcomes Secondary outcomes included examining changes in joint swelling, pain levels, and patient-reported quality of life.

Key Efficacy Findings

Studies have evaluated whether Cauphe affects quality of life in participants, including severity and frequency of flare-ups.

  • Response Rates: The studies evaluated response rates compared to placebo. Outcomes from this research suggest a potential for an effect.
  • Joint Symptoms: Studies have investigated whether Cauphe affects acute joint pain and have assessed changes in swelling. Research has explored its role in morning stiffness after 6 weeks of observation.

Long-Term Research

The design of the clinical trials included an extension phase to gather data on long-term effects. This phase examined the overall persistence of outcomes and the long-term tolerability profile.

  • Long-Term Follow-up: Research has examined the outcomes among participants who continued treatment long-term.
  • Study Assessment: Studies have evaluated the outcomes of continuous treatment over a specified duration. Consultation with a healthcare professional can provide information about treatment options.

How should Cauphe be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of this medicine, identified as Caffeine Citrate (Injection/Solution).

Storage Classification Requirement
Temperature Store at controlled room temperature, typically 20^circ to 25 C (68^circ to 77 F), with excursions permitted between 15^circ and 30 C.
Protection Protect from heat, direct light, and humidity. Avoid extremely high or low temperatures.
Handling Keep the medicine out of the reach of children, often requiring storage in a child-resistant container. Do not use if the solution is cloudy, discolored, or contains particles.
Disposal As a single-use, preservative-free product, any unused medicine in the vial must be discarded immediately after the required dose is removed. Unused or expired medication should be disposed of via a drug take-back program or by mixing it with an undesirable substance before placing it in the trash, adhering to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Cauphe found in:

A-Z Index: